Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates
Ascentage Pharma (NASDAQ: AAPG) reported strong H1 2025 financial results, with Olverembatinib sales surging 93% year-over-year to $30.3 million. The company achieved a significant milestone with the approval of Lisaftoclax, the first Bcl-2 inhibitor for CLL/SLL treatment in China.
Total revenue was $32.6 million, down 71.6% year-over-year due to prior year's one-time IP revenue. The company reported a net loss of $82.5 million ($0.24 per share). Cash position strengthened to $231.9 million, further bolstered by a $190.1 million top-up placement in July 2025.
Nine registrational trials are actively progressing, including three FDA-cleared studies. The company expanded its commercial reach with Olverembatinib now available in 782 DTP pharmacies and hospitals, representing a 17% increase year-over-year.
Ascentage Pharma (NASDAQ: AAPG) ha riportato risultati finanziari solidi per il primo semestre 2025, con le vendite di Olverembatinib in aumento del 93% rispetto all鈥檃nno precedente, raggiungendo 30,3 milioni di dollari. L鈥檃zienda ha raggiunto un traguardo importante con l鈥檃pprovazione di Lisaftoclax, il primo inibitore di Bcl-2 per il trattamento di CLL/SLL in Cina.
I ricavi totali sono stati di 32,6 milioni di dollari, in calo del 71,6% su base annua a causa di ricavi una tantum per propriet脿 intellettuale registrati l鈥檃nno precedente. L鈥檃zienda ha registrato una perdita netta di 82,5 milioni di dollari (pari a 0,24 dollari per azione). La posizione di cassa si 猫 rafforzata a 231,9 milioni di dollari, ulteriormente supportata da un aumento di capitale per 190,1 milioni di dollari a luglio 2025.
Nove studi registrativi sono in corso, compresi tre studi approvati dalla FDA. L鈥檃zienda ha ampliato la distribuzione commerciale di Olverembatinib, ora disponibile in 782 farmacie DTP e ospedali, con un incremento annuo del 17%.
Ascentage Pharma (NASDAQ: AAPG) present贸 s贸lidos resultados financieros en el primer semestre de 2025, con las ventas de Olverembatinib creciendo un 93% interanual hasta 30,3 millones de d贸lares. La compa帽铆a alcanz贸 un hito importante con la aprobaci贸n de Lisaftoclax, el primer inhibidor de Bcl-2 para el tratamiento de CLL/SLL en China.
Los ingresos totales fueron de 32,6 millones de d贸lares, una disminuci贸n del 71,6% interanual debido a ingresos 煤nicos por propiedad intelectual registrados el a帽o anterior. La compa帽铆a report贸 una p茅rdida neta de 82,5 millones de d贸lares (0,24 d贸lares por acci贸n). La posici贸n de caja se fortaleci贸 hasta 231,9 millones de d贸lares, reforzada adem谩s por una colocaci贸n suplementaria de 190,1 millones de d贸lares en julio de 2025.
Nueve ensayos registratorios est谩n en progreso, incluidos tres estudios autorizados por la FDA. La compa帽铆a ampli贸 su presencia comercial y Olverembatinib est谩 disponible ahora en 782 farmacias DTP y hospitales, un aumento del 17% interanual.
Ascentage Pharma (NASDAQ: AAPG)電� 2025雲� 靸侂皹旮� 瓴“頃� 鞁れ爜鞚� 氚滍憸頄堨溂氅�, Olverembatinib 毵れ稖鞚� 鞝勲厔 雽�牍� 93% 旮夓頃� 3,030毵� 雼煬毳� 旮半頄堨姷雼堧嫟. 須岇偓電� 欷戧淡鞐愳劀 CLL/SLL 旃橂毳� 鞙勴暅 斓滌磮鞚� Bcl-2 鞏奠牅鞝滌澑 Lisaftoclax 鞀轨澑鞚措澕電� 欷戩殧頃� 靹标臣毳� 雼劚頄堨姷雼堧嫟.
齑濍Г於涤潃 3,260毵� 雼煬搿� 鞝勲厔 霃欔赴 雽�牍� 71.6% 臧愳唽頄堧姅雿�, 鞚措姅 鞝勲厔鞚� 鞚柬殞靹� 歆�鞝侅灛靷瓣秾 靾橃澋 霑岆鞛呺媹雼�. 靾滌啇鞁れ潃 8,250毵� 雼煬(欤茧嫻 0.24雼煬)搿� 氤搓碃霅愳姷雼堧嫟. 順勱笀 氤挫湢鞎§潃 2鞏�3,190毵� 雼煬搿� 臧曧檾霅橃棃瓿�, 2025雲� 7鞗旍棎 鞁れ嫓頃� 1鞏�9,010毵� 雼煬 攴滊鞚� 於旉皜 鞙犾儊歃濎瀽搿� 雿旍毐 霋冯皼旃悩鞐堨姷雼堧嫟.
齑� 9瓯挫潣 霌彪 鞛勳儊鞚� 歆勴枆 欷戩澊氅�, 鞚� 欷� 3瓯挫潃 FDA臧� 鞀轨澑頃� 鞐瓣惮鞛呺媹雼�. 須岇偓電� 靸侅梾鞝� 氩旍渼毳� 頇曥灔頃� Olverembatinib鞚� 順勳灛 782臧� DTP 鞎疥淡 氚� 氤戩洂鞐愳劀 鞝滉车頃橁碃 鞛堨溂氅�, 鞝勲厔 雽�牍� 17% 歃濌皜頄堨姷雼堧嫟.
Ascentage Pharma (NASDAQ: AAPG) a publi茅 de solides r茅sultats financiers pour le premier semestre 2025, avec des ventes d鈥橭lverembatinib en hausse de 93% en glissement annuel, atteignant 30,3 millions de dollars. La soci茅t茅 a franchi une 茅tape importante avec l鈥檃pprobation de Lisaftoclax, le premier inhibiteur de Bcl-2 pour le traitement de la CLL/SLL en Chine.
Le chiffre d鈥檃ffaires total s鈥檈st 茅lev茅 脿 32,6 millions de dollars, en baisse de 71,6% par rapport 脿 l鈥檃nn茅e pr茅c茅dente en raison de revenus exceptionnels li茅s 脿 la propri茅t茅 intellectuelle l鈥檃nn茅e d鈥檃vant. La soci茅t茅 a d茅clar茅 une perte nette de 82,5 millions de dollars (0,24 dollar par action). La tr茅sorerie s鈥檈st renforc茅e pour atteindre 231,9 millions de dollars, soutenue en outre par un placement compl茅mentaire de 190,1 millions de dollars en juillet 2025.
Neuf essais d鈥檈nregistrement sont en cours, dont trois 茅tudes approuv茅es par la FDA. La soci茅t茅 a 茅tendu sa port茅e commerciale et Olverembatinib est d茅sormais disponible dans 782 pharmacies DTP et h么pitaux, soit une augmentation annuelle de 17%.
Ascentage Pharma (NASDAQ: AAPG) meldete starke Finanzergebnisse f眉r das erste Halbjahr 2025, wobei die Ums盲tze mit Olverembatinib im Jahresvergleich um 93% auf 30,3 Millionen US-Dollar gestiegen sind. Das Unternehmen erreichte einen wichtigen Meilenstein mit der Zulassung von Lisaftoclax, dem ersten Bcl-2-Inhibitor zur Behandlung von CLL/SLL in China.
Der Gesamtumsatz belief sich auf 32,6 Millionen US-Dollar, ein R眉ckgang von 71,6% gegen眉ber dem Vorjahr aufgrund einmaliger IP-Erl枚se im Vorjahr. Das Unternehmen meldete einen Nettoverlust von 82,5 Millionen US-Dollar (0,24 USD je Aktie). Die Cash-Position st盲rkte sich auf 231,9 Millionen US-Dollar und wurde im Juli 2025 durch eine Aufstockungsplatzierung in H枚he von 190,1 Millionen US-Dollar weiter gest盲rkt.
Neun Zulassungsstudien laufen aktiv, darunter drei von der FDA genehmigte Studien. Das Unternehmen hat seine kommerzielle Reichweite ausgebaut: Olverembatinib ist inzwischen in 782 DTP-Apotheken und Krankenh盲usern erh盲ltlich, ein Anstieg von 17% im Jahresvergleich.
- Olverembatinib sales grew 93% YoY to $30.3 million
- Historic approval of Lisaftoclax as first Bcl-2 inhibitor for CLL/SLL in China
- Successful $190.1 million top-up placement strengthening balance sheet
- Nine registrational trials ongoing, including three FDA-cleared studies
- 17% expansion in distribution network to 782 pharmacies and hospitals
- Cash position increased 31.7% to $231.9 million
- Revenue declined 71.6% to $32.6 million due to absence of prior year's IP revenue
- Net loss of $82.5 million compared to profit of $22.4 million in H1 2024
- R&D expenses increased 19% to $73.8 million
- Selling and distribution expenses rose 53.7% to $19.2 million
Insights
Ascentage shows strong commercial growth with Olverembatinib sales up 93% YoY, while advancing nine registrational trials and securing significant funding.
Ascentage Pharma's H1 2025 results highlight impressive commercial momentum with Olverembatinib sales reaching
The July 2025 approval of Lisaftoclax in China represents a landmark achievement as the first Bcl-2 inhibitor approved for CLL/SLL in China and only the second globally. Commercial sales have already commenced, supported by inclusion in the CSCO treatment guidelines.
Despite the strong product growth, total revenue decreased
The company's pipeline advancement remains robust with nine registrational trials ongoing, including three cleared by the FDA. R&D expenses increased
Ascentage's financial position has strengthened considerably. Cash and bank balances reached
The dual progress in commercial execution and clinical development positions Ascentage as an emerging player in oncology with growing revenue streams and multiple potential catalysts from its late-stage pipeline.
Ascentage's Olverembatinib shows commercial traction while Lisaftoclax approval marks significant advancement for Chinese CLL/SLL patients.
Ascentage's clinical progress demonstrates significant advancement in addressing unmet needs in hematologic malignancies. Olverembatinib, their novel third-generation BCR-ABL1 TKI, has shown substantial market penetration for CML patients with T315I mutations and those resistant/intolerant to first and second-generation TKIs. The
The July 2025 approval of Lisaftoclax represents a watershed moment for Chinese CLL/SLL patients who previously had limited options after BTK inhibitor therapy. As the first Bcl-2 inhibitor approved in China, Lisaftoclax addresses a critical treatment gap in the CLL/SLL paradigm. The CSCO guideline inclusion shortly after approval underscores its clinical significance.
The company's clinical development strategy shows sophisticated pipeline expansion beyond initial indications. The GLORA-4 trial investigating Lisaftoclax in combination with azacitidine for first-line higher-risk MDS demonstrates strategic targeting of additional indications with high unmet need. The global regulatory clearances (FDA, EMA, China CDE) for this study highlight the international recognition of this program's potential.
Similarly, the investigation of Olverembatinib for SDH-deficient GIST represents an innovative approach to a challenging subtype with limited treatment options. The exploration of Olverembatinib in Ph+ ALL shows appropriate expansion into a related but distinct BCR-ABL1-driven malignancy.
The depth of Ascentage's registrational trial portfolio (nine ongoing pivotal studies) reflects a comprehensive clinical strategy targeting multiple hematologic malignancies with significant unmet needs. The focus on combination therapies, particularly Lisaftoclax with BTK inhibitors in CLL/SLL, aligns with evolving treatment paradigms emphasizing targeted combination approaches.
- Product sales from Olverembatinib in the first half of 2025 increased听
93% year-over-year to US$30.3 million (RMB217.4 million), primarily attributable to the expansion of NRDL coverage - Commenced commercial sales of Lisaftoclax in China, following approval on July 10, 2025 by China鈥檚 NMPA for the treatment of adult patients with CLL/SLL who have previously received at least one systemic therapy including BTK inhibitors
- Registrational Phase III trial for 1L HR MDS (GLORA-4) cleared by FDA and EMA, and first patients enrolled in Europe and China
- Completed a top-up placement in July 2025, resulting in US
$190.1 million in net proceeds - Nine registrational clinical trials are in progress, including three cleared by FDA
- Chinese (Mandarin) language investor webcast at 9:00 pm EDT on August 20, 2025 / 9:00 am HKT on August 21, 2025, and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 21, 2025
ROCKVILLE, Md. and SUZHOU, China, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (Ascentage Pharma) (NASDAQ: AAPG; HKEX: 6855) (referred hereinto as 鈥淎scentage Pharma,鈥� the 鈥淐ompany,鈥� 鈥渨e,鈥� 鈥渦s鈥� or 鈥渙ur鈥�), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today reported its unaudited financial results for the six months ended June 30, 2025, and provided updates on key ongoing clinical programs and commercial activities.
Dr. Dajun Yang, Chairman and Chief Executive Officer of Ascentage Pharma, said, 鈥淲e reported strong momentum across our business in the first half of 2025, highlighted by the remarkable
Key Commercial Product and Pipeline Updates
Olverembatinib (HQP1351) is a novel, next-generation TKI and the first third-generation BCR-ABL1 TKI approved in China for treatment of patients with chronic myeloid leukemia (CML) in chronic-phase (-CP) or CML in accelerated phase (-AP) with T315I mutations, and in CML-CP that is resistant and/or intolerant to first and second-generation TKIs. Since 2021, commercialization of Olverembatinib in China continues to perform well. Additional potential indications for Olverembatinib are being evaluated in ongoing clinical trials.
Commercial progress
- Revenue from sales of Olverembatinib in China increased
93% to US$30.3 million for the six months ended June 30, 2025, compared to US$15.5 million for the six months ended June 30, 2024. - All approved indications for Olverembatinib have been covered since January 2025 by the China鈥檚 NRDL, which has bolstered the affordability and accessibility of Olverembatinib.
- The number of direct-to-patient (DTP) pharmacies and hospitals where Olverembatinib is on formulary reached 782 as of June 30, 2025, a
17% increase compared to June 30, 2024. In particular, the number of hospitals where Olverembatinib is on formulary increased47% over the same period to 295 hospitals as of June 30, 2025 from 201 hospitals as of June 30, 2024.
Clinical progress
- Enrollment continues in a registrational Phase III clinical trial of Olverembatinib for the treatment of patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST) who have not responded to prior systemic treatment (POLARIS-3).
- Enrollment continues in an FDA-cleared registrational Phase III clinical trial of Olverembatinib for previously treated CML-CP patients, both with and without T315I mutation (POLARIS-2).
- Enrollment continues in a registrational Phase III clinical trial of Olverembatinib in combination with chemotherapy versus imatinib in combination with chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive ALL (Ph+ ALL) (POLARIS-1).
Anticipated progress
- Plan to seek clearance from the FDA to initiate a registrational Phase III clinical trial of Olverembatinib in newly diagnosed Ph+ ALL patients.
Lisaftoclax (APG-2575) is a novel, oral B-cell lymphoma 2 (Bcl-2) inhibitor developed to treat a variety of hematologic malignancies and solid tumors by selectively blocking Bcl-2 to restore the normal apoptosis process in cancer cells. Lisaftoclax is approved in China for the treatment of adult patients with CLL/SLL who have previously received at least one systemic therapy including Bruton鈥檚 tyrosine kinase (BTK) inhibitors and is being evaluated for additional potential indications in ongoing clinical trials.
Commercial progress
- Lisaftoclax was approved on July 10, 2025, by China鈥檚 National Medical Products Administration (NMPA) for the treatment of adult patients with CLL/SLL who have previously received at least one systemic therapy including BTK inhibitors, which makes Lisaftoclax the first Bcl-2 inhibitor to receive conditional approval and marketing authorization for the treatment of patients with CLL/SLL in China, and the second Bcl-2 inhibitor approved globally. Shortly after the approval, commercial sales of Lisaftoclax commenced in China.
- Lisaftoclax received its first recommendation in April 2025 in the Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Lymphoid Malignancies as a monotherapy for the treatment of patients with relapsed/refractory (R/R) CLL/SLL.
Clinical progress
- Enrollment continues in a multicenter, registrational Phase III clinical trial of Lisaftoclax in combination with azacitidine for the treatment of patients who are newly diagnosed with higher-risk (HR) myelodysplastic syndrome (MDS) (GLORA-4). GLORA-4 has been cleared by the FDA and EMA and was originally approved by the China CDE in 2024. Currently, the study is enrolling patients globally, with the first patients dosed in Europe and China.
- Enrollment continues in a registrational Phase III clinical trial of Lisaftoclax for the treatment of newly diagnosed old or unfit patients with acute myeloid leukemia (AML) (GLORA-3).
- Enrollment continues in a registrational Phase III clinical trial to evaluate Lisaftoclax in combination with the BTK inhibitor acalabrutinib, versus immunochemotherapy in treatment-na茂ve patients with CLL/SLL (GLORA-2) to validate a fixed duration combination regimen as a first-line treatment.
- Enrollment continues in an FDA-cleared registrational Phase III clinical trial of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors (GLORA).
- Enrollment advancing in the Phase 1b/II clinical trials of Lisaftoclax in combination therapies for the treatment of patients with multiple myeloma (MM) in the United States.
Recent Developments
- Completed a top-up placement of ordinary shares in July 2025, resulting in US
$190.1 million in net proceeds. - Appointed Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance.
Half Year 2025 Unaudited Financial Results
Revenue for the six months ended June 30, 2025 was US
Selling and distribution expenses for the six months ended June 30, 2025 were US
Research and development expenses for the six months ended June 30, 2025 were US
Administrative expenses for the six months ended June 30, 2025 were US
Financing costs for the six months ended June 30, 2025 were US
Other expenses for the six months ended June 30, 2025 were US
Loss for the six months ended June 30, 2025 was US
Cash and bank balances as of June 30, 2025, were US
Following the top-up placement in July 2025, which resulted in US
Investor Conference Call and Webcast
Ascentage Pharma will be holding investor webcasts to discuss its six months 2025 unaudited interim results.
Ascentage Pharma will host a Chinese (Mandarin) language investor webcast at 9:00 pm EDT on August 20, 2025 / 9:00 am HKT on August 21, 2025.听To access the Chinese language investor event or conference call, please register in advance听.
The English language investor conference call and webcast will be held at 8:00 am EDT / 8:00 pm HKT on August 21, 2025.听To access the English language webcast, please register in advance听.听The webcast replay for English language conference call and presentation will also be available on the听听page of the Ascentage Pharma website.
Statement Regarding Unaudited Financial Information
This press release includes unaudited condensed consolidated financial information as of and for the six months ended June 30, 2025, which has not been audited by the Company鈥檚 auditors. The unaudited information for the six months ended June 30, 2025, is preliminary, based on the information available at this time and subject to changes in connection with the completion of the review of the Company鈥檚 financial statements. As such, the Company鈥檚 actual results and financial condition as reflected in the financial statements that will be included in the Company鈥檚 Annual Report on Form 6-K, may be adjusted or presented differently from the financial information herein and the variations could be material. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All periods presented have been accounted for in conformity with IFRS accounting standard as issued by the International Accounting Standards Board and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the 鈥淪EC鈥�).
Currency and Exchange Rate Information
Unless otherwise indicated, translations from RMB to U.S. dollars for the six months ended June 30, 2025 and 2024 and as at December 31, 2024 are made at RMB7.1636 to US
About Ascentage Pharma
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (鈥�Ascentage Pharma鈥� or the 鈥�Company鈥�) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors.
The Company鈥檚 first approved product, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an FDA-cleared registrational Phase III trial, called POLARIS-2, of Olverembatinib for CML, as well as registrational Phase III trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.
The Company鈥檚 second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China鈥檚 National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton鈥檚 tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA-cleared GLORA-4 study in patients with newly diagnosed HR MDS.
Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.听All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma鈥檚 opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma鈥檚 filings with the听SEC, including those set forth in the sections titled 鈥淩isk factors鈥� and 鈥淐autionary note regarding forward-looking statements鈥� in its Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on April 16, 2025, the sections headed 鈥淔orward-looking Statements鈥� and 鈥淩isk Factors鈥� in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited it has made or it makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this press release do not constitute profit forecast by the Company鈥檚 management.
As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma鈥檚 current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Information
Investor Relations:
Hogan Wan, Head of IR and Strategy
Ascentage Pharma
[email protected]
+86 512 85557777
Stephanie Carrington
ICR Healthcare
[email protected]
+1 (646) 277-1282
Media Relations:
Jon Yu
ICR Healthcare
[email protected]
+1 (646) 677-1855
| 听 | ||||||||||||||||
| Ascentage Pharma Group International | ||||||||||||||||
| Condensed consolidated statements of profit or loss | ||||||||||||||||
| (Amounts in thousands of Renminbi (鈥淩MB鈥�) and U.S. dollar (鈥淯S$鈥�), except for number of shares and per share data) | ||||||||||||||||
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| 听 | 听 | For the Six Months Ended June 30, | ||||||||||||||
| 听 | 听 | 2023听 | 听 | 2024 | 听 | 2025 | 听 | 2025 | ||||||||
| 听 | 听 | RMB | 听 | RMB | 听 | RMB | 听 | US$ | ||||||||
| 听 | 听 | 锛圲苍补耻诲颈迟别诲) | 听 | 锛圲苍补耻诲颈迟别诲) | 听 | 锛圲苍补耻诲颈迟别诲) | 听 | 锛圲苍补耻诲颈迟别诲) | ||||||||
| REVENUE | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Intellectual property | 听 | 听 | - | 听 | 听 | 听 | 678,416 | 听 | 听 | 听 | - | 听 | 听 | 听 | - | 听 |
| Products | 听 | 听 | 129,533 | 听 | 听 | 听 | 124,823 | 听 | 听 | 听 | 212,874 | 听 | 听 | 听 | 29,716 | 听 |
| Others | 听 | 听 | 13,168 | 听 | 听 | 听 | 20,507 | 听 | 听 | 听 | 20,825 | 听 | 听 | 听 | 2,907 | 听 |
| Total revenue | 听 | 听 | 142,701 | 听 | 听 | 听 | 823,746 | 听 | 听 | 听 | 233,699 | 听 | 听 | 听 | 32,623 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| Cost of sales | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| Products | 听 | 听 | (18,154 | ) | 听 | 听 | (14,158 | ) | 听 | 听 | (20,659 | ) | 听 | 听 | (2,884 | ) |
| Others | 听 | 听 | - | 听 | 听 | 听 | (901 | ) | 听 | 听 | (991 | ) | 听 | 听 | (138 | ) |
| Total cost of sales | 听 | 听 | (18,154 | ) | 听 | 听 | (15,059 | ) | 听 | 听 | (21,650 | ) | 听 | 听 | (3,022 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| Gross profit | 听 | 听 | 124,547 | 听 | 听 | 听 | 808,687 | 听 | 听 | 听 | 212,049 | 听 | 听 | 听 | 29,601 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| Other income and gains | 听 | 听 | 17,021 | 听 | 听 | 听 | 17,346 | 听 | 听 | 听 | 36,661 | 听 | 听 | 听 | 5,118 | 听 |
| Selling and distribution expenses | 听 | 听 | (83,319 | ) | 听 | 听 | (89,637 | ) | 听 | 听 | (137,787 | ) | 听 | 听 | (19,234 | ) |
| Administrative expenses | 听 | 听 | (91,340 | ) | 听 | 听 | (86,988 | ) | 听 | 听 | (99,685 | ) | 听 | 听 | (13,915 | ) |
| Research and development expenses | 听 | 听 | (309,814 | ) | 听 | 听 | (444,079 | ) | 听 | 听 | (528,561 | ) | 听 | 听 | (73,784 | ) |
| Other expenses | 听 | 听 | (4,175 | ) | 听 | 听 | (7,106 | ) | 听 | 听 | (40,192 | ) | 听 | 听 | (5,612 | ) |
| Finance costs | 听 | 听 | (52,719 | ) | 听 | 听 | (34,076 | ) | 听 | 听 | (27,798 | ) | 听 | 听 | (3,880 | ) |
| Share of profit/(loss) of a joint venture | 听 | 听 | 196 | 听 | 听 | 听 | (1,252 | ) | 听 | 听 | 1 | 听 | 听 | 听 | - | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| (LOSS)/PROFIT BEFORE TAX | 听 | 听 | (399,603 | ) | 听 | 听 | 162,895 | 听 | 听 | 听 | (585,312 | ) | 听 | 听 | (81,706 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| Income tax expense | 听 | 听 | (2,746 | ) | 听 | 听 | (69 | ) | 听 | 听 | (5,512 | ) | 听 | 听 | (770 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| (LOSS)/PROFIT FOR THE PERIOD | 听 | 听 | (402,349 | ) | 听 | 听 | 162,826 | 听 | 听 | 听 | (590,824 | ) | 听 | 听 | (82,476 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| Attributable to: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| Ordinary equity holders of the Company | 听 | 听 | (402,351 | ) | 听 | 听 | 163,001 | 听 | 听 | 听 | (590,768 | ) | 听 | 听 | (82,468 | ) |
| Non-controlling interests | 听 | 听 | 2 | 听 | 听 | 听 | (175 | ) | 听 | 听 | (56 | ) | 听 | 听 | (8 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| 听 | 听 | 听 | (402,349 | ) | 听 | 听 | 162,826 | 听 | 听 | 听 | (590,824 | ) | 听 | 听 | (82,476 | ) |
| (LOSS)/EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE COMPANY | 听 | |||||||||||||||
| Basic | 听 | 听 | (1.47 | ) | 听 | 听 | 0.56 | 听 | 听 | 听 | (1.73 | ) | 听 | 听 | (0.24 | ) |
| Diluted | 听 | 听 | (1.47 | ) | 听 | 听 | 0.55 | 听 | 听 | 听 | (1.73 | ) | 听 | 听 | (0.24 | ) |
| 听 | ||||||||||||||||
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | |||||||||
| Ascentage Pharma Group International | |||||||||||||||
| Condensed consolidated statements of comprehensive loss | |||||||||||||||
| (Amounts in thousands of Renminbi and U.S. dollar, except for number of shares and per share data) | 听 | 听 | |||||||||||||
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| 听 | For the Six Months Ended June 30, | ||||||||||||||
| 听 | 2023 | 听 | 2024 | 听 | 2025 | 听 | 2025 | ||||||||
| 听 | RMB | 听 | RMB | 听 | RMB | 听 | US$ | ||||||||
| 听 | 锛圲苍补耻诲颈迟别诲) | 听 | 锛圲苍补耻诲颈迟别诲) | 听 | 锛圲苍补耻诲颈迟别诲) | 听 | 锛圲苍补耻诲颈迟别诲) | ||||||||
| (LOSS)/PROFIT FOR THE PERIOD | 听 | (402,349 | ) | 听 | 听 | 162,826 | 听 | 听 | 听 | (590,824 | ) | 听 | 听 | (82,476 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| OTHER COMPREHENSIVE INCOME/(LOSS) | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| Other comprehensive income that may be reclassified to profit or loss in subsequent periods: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| Exchange differences on translation of foreign operations | 听 | (699 | ) | 听 | 听 | 40 | 听 | 听 | 听 | 1,095 | 听 | 听 | 听 | 153 | 听 |
| Other comprehensive income that will not be reclassified to profit or loss in subsequent periods: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| Exchange differences on translation of the Company | 听 | 40,479 | 听 | 听 | 听 | 2,229 | 听 | 听 | 听 | (2,035 | ) | 听 | 听 | (284 | ) |
| OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE PERIOD, NET OF TAX | 听 | 39,780 | 听 | 听 | 听 | 2,269 | 听 | 听 | 听 | (940 | ) | 听 | 听 | (131 | ) |
| TOTAL COMPREHENSIVE (LOSS)/INCOME FOR THE PERIOD | 听 | (362,569 | ) | 听 | 听 | 165,095 | 听 | 听 | 听 | (591,764 | ) | 听 | 听 | (82,607 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| Attributable to: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| Ordinary equity holders of the Company | 听 | (362,571 | ) | 听 | 听 | 165,270 | 听 | 听 | 听 | (591,708 | ) | 听 | 听 | (82,599 | ) |
| Non-controlling interests | 听 | 2 | 听 | 听 | 听 | (175 | ) | 听 | 听 | (56 | ) | 听 | 听 | (8 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| 听 | 听 | (362,569 | ) | 听 | 听 | 165,095 | 听 | 听 | 听 | (591,764 | ) | 听 | 听 | (82,607 | ) |
| 听 | |||||||||||||||
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | |
| Ascentage Pharma Group International | |||||||||
| Condensed consolidated statements of financial position | |||||||||
| (Amounts in thousands of Renminbi and U.S. dollar, except for number of shares and per share data) | |||||||||
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| 听 | 听 | As at | |||||||
| 听 | 听 | December 31, 2024 | 听 | June 30, 2025 | 听 | June 30, 2025 | |||
| 听 | 听 | RMB | 听 | RMB | 听 | US$ | |||
| 听 | 听 | (Audited) | 听 | 锛圲苍补耻诲颈迟别诲) | 听 | 锛圲苍补耻诲颈迟别诲) | |||
| NON-CURRENT ASSETS | 听 | 听 | 听 | 听 | 听 | 听 | |||
| Property, plant and equipment | 听 | 听 | 849,450 | 听 | 听 | 821,201 | 听 | 听 | 114,635 |
| Right-of-use assets | 听 | 听 | 56,109 | 听 | 听 | 50,760 | 听 | 听 | 7,086 |
| Goodwill | 听 | 听 | 24,694 | 听 | 听 | 24,694 | 听 | 听 | 3,447 |
| Other intangible assets | 听 | 听 | 75,998 | 听 | 听 | 70,994 | 听 | 听 | 9,910 |
| Investment in a joint venture | 听 | 听 | 32,717 | 听 | 听 | 32,718 | 听 | 听 | 4,567 |
| Financial assets at fair value through profit or loss (鈥淔VTPL鈥�) | 1,141 | 听 | 听 | 4,617 | 听 | 听 | 645 | ||
| Deferred tax assets | 听 | 听 | 44,236 | 听 | 听 | 33,385 | 听 | 听 | 4,660 |
| Other non-current assets | 听 | 听 | 59,303 | 听 | 听 | 99,055 | 听 | 听 | 13,828 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Total non-current assets | 听 | 听 | 1,143,648 | 听 | 听 | 1,137,424 | 听 | 听 | 158,778 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| CURRENT ASSETS | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Inventories | 听 | 听 | 6,597 | 听 | 听 | 8,591 | 听 | 听 | 1,199 |
| Trade receivables, net | 听 | 听 | 83,143 | 听 | 听 | 78,362 | 听 | 听 | 10,939 |
| Prepayments, other receivables and other assets | 123,211 | 听 | 听 | 160,313 | 听 | 听 | 22,379 | ||
| Cash and bank balances | 听 | 听 | 1,261,211 | 听 | 听 | 1,661,454 | 听 | 听 | 231,930 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Total current assets | 听 | 听 | 1,474,162 | 听 | 听 | 1,908,720 | 听 | 听 | 266,447 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| CURRENT LIABILITIES | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Trade payables | 听 | 听 | 91,966 | 听 | 听 | 118,676 | 听 | 听 | 16,567 |
| Other payables and accruals | 听 | 听 | 258,098 | 听 | 听 | 249,358 | 听 | 听 | 34,808 |
| Contract liabilities | 听 | 听 | 37,485 | 听 | 听 | 37,485 | 听 | 听 | 5,233 |
| Interest-bearing bank and other borrowings | 听 | 779,062 | 听 | 听 | 833,783 | 听 | 听 | 116,392 | |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Total current liabilities | 听 | 听 | 1,166,611 | 听 | 听 | 1,239,302 | 听 | 听 | 173,000 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| NET CURRENT ASSETS | 听 | 听 | 307,551 | 听 | 听 | 669,418 | 听 | 听 | 93,447 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| TOTAL ASSETS LESS CURRENT LIABILITIES | 听 | 1,451,199 | 听 | 听 | 1,806,842 | 听 | 听 | 252,225 | |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| 听 | ||||||||||||
| Ascentage Pharma Group International | ||||||||||||
| Condensed consolidated statements of financial position | ||||||||||||
| (Amounts in thousands of Renminbi and U.S. dollar, except for number of shares and per share data) | ||||||||||||
| 听 | ||||||||||||
| 听 | ||||||||||||
| 听 | 听 | As at | ||||||||||
| 听 | 听 | December 31, 2024 | 听 | June 30, 2025 | 听 | June 30, 2025 | ||||||
| 听 | 听 | RMB | 听 | RMB | 听 | US$ | ||||||
| 听 | 听 | (Audited) | 听 | (Unaudited) | 听 | (Unaudited) | ||||||
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||
| NON-CURRENT LIABILITIES | 听 | 听 | 听 | 听 | 听 | 听 | ||||||
| Contract liabilities | 听 | 听 | 248,460 | 听 | 听 | 听 | 229,628 | 听 | 听 | 听 | 32,055 | 听 |
| Interest-bearing bank and other borrowings | 听 | 889,435 | 听 | 听 | 听 | 882,382 | 听 | 听 | 听 | 123,176 | 听 | |
| Deferred tax liabilities | 听 | 听 | 5,368 | 听 | 听 | 听 | - | 听 | 听 | 听 | - | 听 |
| Deferred income | 听 | 听 | 27,500 | 听 | 听 | 听 | 6,500 | 听 | 听 | 听 | 907 | 听 |
| Other non-current liabilities | 听 | 听 | 6,274 | 听 | 听 | 听 | 12,423 | 听 | 听 | 听 | 1,734 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | |||
| Total non-current liabilities | 听 | 听 | 1,177,037 | 听 | 听 | 听 | 1,130,933 | 听 | 听 | 听 | 157,872 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | |||
| TOTAL LIABILITIES | 听 | 听 | 2,343,648 | 听 | 听 | 听 | 2,370,235 | 听 | 听 | 听 | 330,872 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | |||
| EQUITY | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | |||
| Equity attributable to ordinary equity holders of the Company | 听 | 听 | 听 | 听 | 听 | |||||||
| Ordinary shares (par value of US | 214 | 听 | 听 | 听 | 239 | 听 | 听 | 听 | 33 | 听 | ||
| Treasury shares | 听 | 听 | (8 | ) | 听 | 听 | (2,960 | ) | 听 | 听 | (413 | ) |
| Share premium | 听 | 听 | 6,545,129 | 听 | 听 | 听 | 7,546,108 | 听 | 听 | 听 | 1,053,396 | 听 |
| Capital and reserves | 听 | 听 | (384,515 | ) | 听 | 听 | (389,056 | ) | 听 | 听 | (54,310 | ) |
| Exchange fluctuation reserve | 听 | 听 | (126,071 | ) | 听 | 听 | (127,011 | ) | 听 | 听 | (17,730 | ) |
| Accumulated losses | 听 | 听 | (5,770,555 | ) | 听 | 听 | (6,361,323 | ) | 听 | 听 | (888,006 | ) |
| 听 | 听 | 听 | 264,194 | 听 | 听 | 听 | 665,997 | 听 | 听 | 听 | 92,970 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | |||
| Non-controlling interests | 听 | 听 | 9,968 | 听 | 听 | 听 | 9,912 | 听 | 听 | 听 | 1,383 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | |||
| Total equity | 听 | 听 | 274,162 | 听 | 听 | 听 | 675,909 | 听 | 听 | 听 | 94,353 | 听 |
FAQ
What were Ascentage Pharma's (AAPG) key financial results for H1 2025?
How did Olverembatinib perform in the Chinese market during H1 2025?
What is the significance of Lisaftoclax's approval for AAPG in 2025?
How many clinical trials is AAPG currently conducting?
What was the impact of AAPG's recent financing activities?
